Chemotherapy forms the backbone of treatment for Diffuse Large B Cell Lymphoma (DLBCL); however, <∼20% of tumors are chemoresistant. Inhibitors of the DNA damage response (DDR) show promise as chemosensitizers. We therefore set up an in-vitro screen to identify an optimal chemotherapy-DDR inhibitor (DDRi) combination in a panel of DLBCL cell lines.
Identification of an effective chemotherapy and DNA damage response inhibitor combination for diffuse large b cell lymphoma / A. Chan, A. Anbuselvan, S.S. Upadhyayula, S. Jemimah, P. Jaynes, M.M. Hoppe, J.D. Wardyn, J. Goh, G. Bertolazzi, M. Foiani, M.J. O’Connor, E.K. Chow, C. Tripodo, A.D. Jeyasekharan. - In: EUROPEAN JOURNAL OF CANCER. - ISSN 0959-8049. - 174:suppl. 1(2022), pp. S55-S56. (Intervento presentato al 32. convegno EORTC-NCI-AACR Symposium on MolecularTargets and Cancer Therapeutics tenutosi a Online nel 2020) [10.1016/S0959-8049(22)00949-2].
Identification of an effective chemotherapy and DNA damage response inhibitor combination for diffuse large b cell lymphoma
M. Foiani;C. TripodoPenultimo
;
2022
Abstract
Chemotherapy forms the backbone of treatment for Diffuse Large B Cell Lymphoma (DLBCL); however, <∼20% of tumors are chemoresistant. Inhibitors of the DNA damage response (DDR) show promise as chemosensitizers. We therefore set up an in-vitro screen to identify an optimal chemotherapy-DDR inhibitor (DDRi) combination in a panel of DLBCL cell lines.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Chan_Anand_Tripodo_et_al.pdf
accesso riservato
Descrizione: Poster
Tipologia:
Publisher's version/PDF
Dimensione
73.18 kB
Formato
Adobe PDF
|
73.18 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
